Icon Advisers’s AstraZeneca AZN Stock Holding History

Icon Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,000	Closed	-$2.34M	–	178
2024 Q3	$2.34M	Hold	15,000	–	–	0.49%	87
2024 Q2	$2.34M	Hold	15,000	–	–	0.53%	87
2024 Q1	$2.02M	Hold	15,000	–	–	0.44%	95
2023 Q4	$2.02M	Hold	15,000	–	–	0.46%	88
2023 Q3	$2.03M	Hold	15,000	–	–	0.5%	77
2023 Q2	$2.15M	Hold	15,000	–	–	0.55%	75
2023 Q1	$2.08M	Buy	+15,000	New	+$2.02M	0.53%	76
2020 Q3	–	Sell	-13,350	Closed	-$1.41M	–	184
2020 Q2	$1.41M	Buy	+13,350	New	+$1.38M	0.28%	125
2017 Q1	–	Sell	-9,500	Closed	-$519K	–	380
2016 Q4	$519K	Buy	+9,500	New	+$539K	0.04%	344

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Icon Advisers's AZN Position: Q4 2024 in Review

Icon Advisers sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 15,000 shares — an estimated $2.34M sold.

Icon Advisers first reported a position in AZN in Q4 2016 and held it in 9 quarters. The position peaked at $2.34M in Q2 2024. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

Icon Advisers reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
Icon Advisers sold 15,000 AstraZeneca shares in Q4 2024, an estimated $2.34M.
Icon Advisers first reported a position in AstraZeneca in Q4 2016 and held it in 9 quarters.
Icon Advisers's AstraZeneca position peaked at $2.34M in Q2 2024.
1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Icon Advisers's 13F filing for Q4 2024, filed 13 Feb 2025.